Oncology

Revolution Medicines booth at ASCO 2026
Favicon Fierce Pharma

FDA greenlights RevMed’s pancreatic cancer gamechanger

Following dynamite data that earned a standing ovation at ASCO, RevMed's star Ras inhibitor daraxonrasib has been approved by the FDA.
Darren Incorvaia Aug 26, 2026 11:30am
Connection together puzzle pieces Concept of business strategy collaboration
Favicon Fierce Pharma

McKesson acquires Maryland CRO for $2.25 billion

Aug 25, 2026 11:22am
Roy Maute

Pheast’s CEO has no regrets despite competitors gaining an edge

Aug 21, 2026 8:00am
Moderna booth at AACR 2026

Merck-Moderna cancer vax slows recurrence in ph. 3 trial

Aug 19, 2026 6:45am
Merck Co

Merck and Sarah Cannon team up for oncology trial efficiency

Aug 18, 2026 4:00pm
vials vaccine research vaccines factory manufacturing

Evaxion scraps tumor vaccine to focus on brain cancer candidate

Aug 17, 2026 9:18am
More News

PDS halts ph. 3 cancer therapy to focus on colorectal contender

Aug 13, 2026 9:55am

Sobi pens $580M deal for Innate’s cancer drug before ph. 3 push

Aug 10, 2026 7:13am

Context ends bispecific trial to extend runway deeper into 2027

Aug 6, 2026 5:55am

AZ ‘very confident’ in homegrown ADCs despite dropping 2 assets

Jul 27, 2026 5:26am